(News Bulletin 247) – Bayer announces the launch of three additional studies to expand its heart failure (HF) program with finerenone, as part of the MOONRAKER program.
In addition to the ongoing phase III study (FINEARTS-HF), which is investigating finerenone versus placebo in over 6,000 HF patients with a mildly reduced or preserved ejection fraction, new studies will evaluate the efficacy and safety of finerenone in approximately 9,300 additional patients with HF with reduced (HfrEF), mildly reduced (HfmrEF) and/or preserved (HfpEF) ejection fraction.
With more than 15,000 patients in total, MOONRAKER is on track to become one of the largest heart failure study programs to date, the laboratory points out.
“With the addition of these studies as part of the MOONRAKER heart failure clinical trial program, we aim to gain a comprehensive understanding of finerenone for the treatment of heart failure, examining its efficacy and safety. from a global perspective. a wide range of patients and clinical settings,” said Dr. Michael Devoy, Chief Medical Officer of Bayer.
Copyright (c) 2023 News Bulletin 247. All rights reserved.
I have over 8 years of experience working in the news industry. I have worked as a reporter, editor, and now managing editor at 247 News Agency. I am responsible for the day-to-day operations of the news website and overseeing all of the content that is published. I also write a column for the website, covering mostly market news.
